Latest news with #Cytomegalovirus
Yahoo
19-05-2025
- Business
- Yahoo
Saudi Arabia Molecular Blood Typing, Grouping, Infectious Disease NAT Screening Analyzers and Reagents Report 2025
Unlock emerging opportunities in the next five years with this comprehensive report on blood typing and infectious disease screening. Evaluate market strategies, competitor profiles, technological advancements, and develop effective business plans. Discover trends in automated analyzers and genotyping. Dublin, May 19, 2025 (GLOBE NEWSWIRE) -- The "2025 Saudi Arabia Molecular Blood Typing, Grouping, Infectious Disease NAT Screening Analyzers and Reagents-Transfusion Market Opportunities, Competitive Shares, Strategies, Volume and Sales Segment Forecasts for 40 Immunohematology and NAT Tests Review" has been added to offering. This comprehensive report offers critical insights for current suppliers and potential market entrants in the blood typing and infectious disease screening sectors in Saudi Arabia, aiming to identify and evaluate emerging opportunities over the next five years. This report is an essential tool for industry executives looking to develop robust business, product development, and marketing strategies. The report features detailed test volume and sales forecasts, providing a comparative analysis of major automated and semi-automated analyzers in Saudi Arabia. It includes profiles of leading and up-and-coming competitors, spotlighting specific product and market opportunities for suppliers in the coming years. Key focal points include blood typing and grouping tests (ABO, Antibody Panels, Antigen Typing, among others) and infectious disease screening tests (AIDS, Cytomegalovirus, Hepatitis, etc.). Competitive Assessments Conducts strategic evaluations of major suppliers and emerging market entrants, analyzing their sales, mergers and acquisitions, product portfolios, marketing approaches, and new products in development. Market Segmentation Analysis Delivers test volume and sales forecasts for over 40 blood typing, grouping, and infectious disease screening tests, including NAT assays. Current and Emerging Products Quantifies current and emerging assays in blood typing, grouping, and infectious disease NAT screening. Surveys automated and semi-automated molecular and immunohematology analyzers. Technology Review Evaluates current and emerging technologies, considering their potential applications within the blood banking market. Lists companies engaged in developing or marketing new technologies and products, categorized by test. Detailed assessments of blood group genotyping methodologies are also provided, such as PCR variations and DNA sequencing methods. The report explores innovative platforms like Microarrays utilizing technologies such as BeadChip Array and MALDI-TOF-MS. Strategic Recommendations Highlights new product development prospects for blood typing, grouping, and infectious disease NAT assays and instrumentation that promise significant market appeal. Suggests alternative market penetration strategies and identifies potential market entry barriers and risks. This report serves as a strategic roadmap for stakeholders aiming to secure a competitive edge in the evolving landscapes of blood typing and infectious disease screening. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Associated Press
09-04-2025
- Business
- Associated Press
mRNA Vaccine and Therapeutics (Influenza, Respiratory Syncytial Virus Infection and Cytomegalovirus Diseases) Market Industry Trends and Global Forecasts Report 2025-2035
The 'mRNA Vaccine and Therapeutics Market Industry Trends and Global Forecasts to 2035, by Application Area, Target Disease Indication (Influenza, Respiratory Syncytial Virus Infection and Cytomegalovirus Diseases) and Geographical Regions' report has been added to offering. The global mRNA vaccine and therapeutics market is estimated to be worth USD 1.99 billion by 2035, primarily driven by the anticipated approval of mRNA vaccines and therapeutics intended for the treatment of infectious diseases. In recent years, mRNA technology has revolutionized the pharmaceutical industry to prevent and treat a wide array of diseases and disorders. The success of COVID-19 vaccines has paved the path for mRNA vaccines and therapeutics. It is worth highlighting that, in the past few years, more than 170 clinical trials related to mRNA-based therapeutics / vaccines have been registered. Multiple preclinical and clinical studies show the efficacy of these platforms which have been published in the last two years across different research articles. This demonstrates the extensive development efforts being undertaken by stakeholders in this domain. At present, over 45 industry players are engaged in the development of mRNA drug candidates for a wide range of disease indications. The success of COVID-19 vaccines, growing research activity and the rich pipeline of mRNA drug candidates is likely to drive the global mRNA vaccine and therapeutics market in the coming decade. Several indications, such as Influenza, Respiratory Syncytial Virus, Cytomegalovirus, are the Expected to Drive the mRNA Vaccine and Therapeutics Market Based on the application area, the market is segmented into COVID-19 and other indications. Owing to their proven efficacy against the COVID-19 infection, the vaccines and therapeutics developed for COVID-19 infection have captured the majority of the market share. However, the anticipated approval of mRNA vaccines for other indications is likely to drive the market in the coming decade. Currently, Influenza Segment Occupies the Largest Share of the mRNA Vaccine and Therapeutics Market Based on the target disease indication, the market is segmented into influenza, respiratory syncytial virus infection and cytomegalovirus diseases. It is worth highlighting that the vaccines and therapeutics developed for influenza are likely to drive the market in the coming decade. This can be attributed to the rise in investment in the research and development of influenza vaccines, along with growing awareness among governments and non-profit organizations about the importance of influenza prevention and control. North America Accounts for the Largest Share of the Market Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America and Rest of the World. It is worth highlighting that the market for North America holds the maximum share of the mRNA vaccines and therapeutics market. This trend is likely to remain the same in the coming decade. mRNA Vaccine and Therapeutics Market: Key Insights The report delves into the current state of the mRNA vaccine and therapeutics market and identifies potential growth opportunities within the industry. Some key findings from the report include: Presently, over 235 mRNA drug candidates are available in the market or under development; majority of these drug candidates are vaccines using lipid nanoparticles as delivery systems. The pipeline features several drugs, which are being investigated across different phases of development; 60% of the drug candidates are designed to be administered via intramuscular routes. The current market landscape of mRNA vaccine and therapeutics developers is fragmented, featuring the presence of both new entrants and established players; majority of these players are based in the US. Stakeholders are actively upgrading their existing capabilities to further enhance their respective product pipeline and comply with the evolving industry benchmarks. The growing interest of stakeholders is evident from the surge in partnership activity; clinical trial agreements emerged as the most prevalent partnership model adopted by drug developers. Several investors, having realized the opportunity within this upcoming segment, have invested over USD 11 billion across various funding rounds. More than 345,000 patients have been recruited / enrolled in clinical trials registered for various mRNA-based therapies, across different geographies. Over 430 patents related to mRNA vaccine and therapeutics have been filed / granted by industry and non-industry stakeholders, indicating the growing intellectual capital in this domain. Big pharma players have undertaken several initiatives, ranging from proprietary product development to strategic investments, to tap the lucrative opportunity in this rapidly growing market. The projected opportunity for mRNA vaccine and therapeutics market is likely to be driven by the increasing research and development for mRNA-based drugs focused on non-COVID indications. Some Key Players in the mRNA Vaccine and Therapeutics Market include: Arcturus Therapeutics BioNTech CureVac Ethris IMMORNA Moderna Providence Therapeutics RNACure Suzhou Abogen Biosciences Turn Biotechnologies Gennova Innovac Therapeutics Kernal Biologics Pantherna Therapeutics pHion Therapeutics Recode Therapeutics Rejuvenation Technologies RNAimmune Strand Therapeutics Walvax Ziphius Vaccines Primary Research Overview The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders: Business Development Manager, Canvax Senior Director, Business Development, eTheRNA Team Leader, GC Biopharma mRNA Vaccine and Therapeutics Market: Research Coverage Market Sizing and Opportunity Analysis Market Landscape (Drug Therapies) Market Landscape (Drug Developers): Company Competitiveness Analysis Company Profiles Big Pharma Analysis Start-up Health Indexing Clinical Trial Analysis Funding and Investment Analysis Patent Analysis Market Impact Analysis Key Topics Covered: 1. Preface 2. Research Methodology 3. Economic And Other Project Specific Considerations 4. Executive Summary 5. Introduction 6. Market Landscape 7. Competitive Landscape 8. Company Competitiveness Analysis 9. Company Profiles 10. Big Pharma Initiatives 11. Start-Up Health Indexing 12. Clinical Trial Analysis 13. Partnerships And Collaborations 14. Funding And Investment Analysis 15. Patent Analysis 16. Market Impact Analysis: Drivers, Restraints, Opportunities And Challenges 17. Global MRNA Vaccine And Therapeutics Market 18. MRNA Vaccine And Therapeutics Market, By Application Area 19. MRNA Vaccine And Therapeutics Market, By Target Disease Indication 20. MRNA Vaccine And Therapeutics Market, By Geographical Regions 21. Conclusion 22. Executive Insights 23. Appendix 1: Tabulated Data 24. Appendix 2: List Of Companies And Organizations Additional Benefits Complimentary PPT Insights Packs Complimentary Excel Data Packs for all Analytical Modules in the Report 10% Free Content Customization Detailed Report Walkthrough Session with Research Team For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL Copyright Business Wire 2025. PUB: 04/09/2025 09:17 AM/DISC: 04/09/2025 09:17 AM
Yahoo
01-04-2025
- Business
- Yahoo
mRNA Vaccine and Therapeutics Market Report 2025-2035: 430+ Patents Filed, Signaling Robust Growth in mRNA Intellectual Property
The pipeline features several drugs, which are being investigated across different phases of development; 60% of the drug candidates are designed to be administered via intramuscular routes. Presently, over 235 mRNA drug candidates are available in the market or under development; majority of these drug candidates are vaccines using lipid nanoparticles as delivery systems. Several investors, having realized the opportunity within this upcoming segment, have invested over USD 11 billion across various funding rounds. mRNA Vaccines and Therapeutics Market mRNA Vaccines and Therapeutics Dublin, April 01, 2025 (GLOBE NEWSWIRE) -- The "mRNA Vaccine and Therapeutics Market Industry Trends and Global Forecasts to 2035, by Application Area, Target Disease Indication (Influenza, Respiratory Syncytial Virus Infection and Cytomegalovirus Diseases) and Geographical Regions" report has been added to offering. The global mRNA vaccine and therapeutics market is estimated to be worth USD 1.99 billion by 2035, primarily driven by the anticipated approval of mRNA vaccines and therapeutics intended for the treatment of infectious diseases. In recent years, mRNA technology has revolutionized the pharmaceutical industry to prevent and treat a wide array of diseases and disorders. The success of COVID-19 vaccines has paved the path for mRNA vaccines and therapeutics. It is worth highlighting that, in the past few years, more than 170 clinical trials related to mRNA-based therapeutics / vaccines have been registered. Multiple preclinical and clinical studies show the efficacy of these platforms which have been published in the last two years across different research articles. This demonstrates the extensive development efforts being undertaken by stakeholders in this domain. At present, over 45 industry players are engaged in the development of mRNA drug candidates for a wide range of disease indications. The success of COVID-19 vaccines, growing research activity and the rich pipeline of mRNA drug candidates is likely to drive the global mRNA vaccine and therapeutics market in the coming decade. Several indications, such as Influenza, Respiratory Syncytial Virus, Cytomegalovirus, are the Expected to Drive the mRNA Vaccine and Therapeutics Market Based on the application area, the market is segmented into COVID-19 and other indications. Owing to their proven efficacy against the COVID-19 infection, the vaccines and therapeutics developed for COVID-19 infection have captured the majority of the market share. However, the anticipated approval of mRNA vaccines for other indications is likely to drive the market in the coming decade. Currently, Influenza Segment Occupies the Largest Share of the mRNA Vaccine and Therapeutics Market Based on the target disease indication, the market is segmented into influenza, respiratory syncytial virus infection and cytomegalovirus diseases. It is worth highlighting that the vaccines and therapeutics developed for influenza are likely to drive the market in the coming decade. This can be attributed to the rise in investment in the research and development of influenza vaccines, along with growing awareness among governments and non-profit organizations about the importance of influenza prevention and control. North America Accounts for the Largest Share of the Market Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America and Rest of the World. It is worth highlighting that the market for North America holds the maximum share of the mRNA vaccines and therapeutics market. This trend is likely to remain the same in the coming decade. mRNA Vaccine and Therapeutics Market: Key Insights The report delves into the current state of the mRNA vaccine and therapeutics market and identifies potential growth opportunities within the industry. Some key findings from the report include: Presently, over 235 mRNA drug candidates are available in the market or under development; majority of these drug candidates are vaccines using lipid nanoparticles as delivery systems. The pipeline features several drugs, which are being investigated across different phases of development; 60% of the drug candidates are designed to be administered via intramuscular routes. The current market landscape of mRNA vaccine and therapeutics developers is fragmented, featuring the presence of both new entrants and established players; majority of these players are based in the US. Stakeholders are actively upgrading their existing capabilities to further enhance their respective product pipeline and comply with the evolving industry benchmarks. The growing interest of stakeholders is evident from the surge in partnership activity; clinical trial agreements emerged as the most prevalent partnership model adopted by drug developers. Several investors, having realized the opportunity within this upcoming segment, have invested over USD 11 billion across various funding rounds. More than 345,000 patients have been recruited / enrolled in clinical trials registered for various mRNA-based therapies, across different geographies. Over 430 patents related to mRNA vaccine and therapeutics have been filed / granted by industry and non-industry stakeholders, indicating the growing intellectual capital in this domain. Big pharma players have undertaken several initiatives, ranging from proprietary product development to strategic investments, to tap the lucrative opportunity in this rapidly growing market. The projected opportunity for mRNA vaccine and therapeutics market is likely to be driven by the increasing research and development for mRNA-based drugs focused on non-COVID indications. Some Key Players in the mRNA Vaccine and Therapeutics Market include: Arcturus Therapeutics BioNTech CureVac Ethris IMMORNA Moderna Providence Therapeutics RNACure Suzhou Abogen Biosciences Turn Biotechnologies Gennova Innovac Therapeutics Kernal Biologics Pantherna Therapeutics pHion Therapeutics Recode Therapeutics Rejuvenation Technologies RNAimmune Strand Therapeutics Walvax Ziphius Vaccines Primary Research Overview The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders: Business Development Manager, Canvax Senior Director, Business Development, eTheRNA Team Leader, GC Biopharma mRNA Vaccine and Therapeutics Market: Research Coverage Market Sizing and Opportunity Analysis Market Landscape (Drug Therapies) Market Landscape (Drug Developers): Company Competitiveness Analysis Company Profiles Big Pharma Analysis Start-up Health Indexing Clinical Trial Analysis Funding and Investment Analysis Patent Analysis Market Impact Analysis Key Topics Covered: 1. Preface 2. Research Methodology 3. Economic And Other Project Specific Considerations 4. Executive Summary 5. Introduction 6. Market Landscape 7. Competitive Landscape 8. Company Competitiveness Analysis 9. Company Profiles 10. Big Pharma Initiatives 11. Start-Up Health Indexing 12. Clinical Trial Analysis 13. Partnerships And Collaborations 14. Funding And Investment Analysis 15. Patent Analysis 16. Market Impact Analysis: Drivers, Restraints, Opportunities And Challenges 17. Global MRNA Vaccine And Therapeutics Market 18. MRNA Vaccine And Therapeutics Market, By Application Area 19. MRNA Vaccine And Therapeutics Market, By Target Disease Indication 20. MRNA Vaccine And Therapeutics Market, By Geographical Regions 21. Conclusion 22. Executive Insights 23. Appendix 1: Tabulated Data 24. Appendix 2: List Of Companies And Organizations Additional Benefits Complimentary PPT Insights Packs Complimentary Excel Data Packs for all Analytical Modules in the Report 10% Free Content Customization Detailed Report Walkthrough Session with Research Team Free Updated report if the report is 6-12 months old or older For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachments mRNA Vaccines and Therapeutics Market mRNA Vaccines and Therapeutics CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
